Payment overview · 2025
General Payments
$198.15
8 reported records · 6 companies
Healthcare provider profile · identity verified
Syed Wasim, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CONYERS, GA · NPI 1992763809
Verified facts
What the public records show
CMS Open Payments records show Syed Wasim, MD received $198.15 in general payments during 2025 across 8 reported records.
Abbott Laboratories accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $68.47 | 34.5% | 3 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $42.26 | 21.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.24 | 12.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.91 | 12.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.55 | 10.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.72 | 7.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $198.15 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $68.47 | 3 | 2025 |
Source payment records
|
|||||
| CONEXTIONS TR TENDON REPAIR SYSTEM-IMPLANT MECHANISM Normalized: conextions tr tendon repair system implant mechanism |
Device | Stryker Corporation | $42.26 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.55 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
54 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 689 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 478 | 142 |
| Lisinopril | Lisinopril | 387 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 317 | 91 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 249 | 71 |
| Losartan Potassium | Losartan Potassium | 239 | 73 |
| Metformin Hcl | Metformin Hcl | 214 | 65 |
| Gabapentin | Gabapentin | 200 | 70 |
| Omeprazole | Omeprazole | 190 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 187 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 183 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 55 |
| Farxiga | Dapagliflozin Propanediol | 150 | 34 |
| Furosemide | Furosemide | 143 | 44 |
| Allopurinol | Allopurinol | 134 | 41 |
| Metformin Hcl Er | Metformin Hcl | 133 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 44 |
| Valsartan | Valsartan | 129 | 42 |
| Carvedilol | Carvedilol | 106 | 32 |
| Ezetimibe | Ezetimibe | 105 | 34 |
| Meloxicam | Meloxicam | 103 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 29 |
| Montelukast Sodium | Montelukast Sodium | 92 | 29 |
| Jardiance | Empagliflozin | 91 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 32 |
| Glimepiride | Glimepiride | 88 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 85 | 25 |
| Famotidine | Famotidine | 83 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 82 | 28 |
| Donepezil Hcl | Donepezil Hcl | 80 | 24 |
| Finasteride | Finasteride | 79 | 24 |
| Trazodone Hcl | Trazodone Hcl | 79 | 23 |
| Eliquis | Apixaban | 78 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 21 |
| Alendronate Sodium | Alendronate Sodium | 74 | 23 |
| Azithromycin | Azithromycin | 72 | 63 |
| Terazosin Hcl | Terazosin Hcl | 71 | 19 |
| Sertraline Hcl | Sertraline Hcl | 63 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 19 |
| Potassium Chloride | Potassium Chloride | 58 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 57 | 17 |
| Synthroid | Levothyroxine Sodium | 56 | 14 |
| Nifedipine Er | Nifedipine | 54 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 54 | 38 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 53 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 26 |
| Spironolactone | Spironolactone | 50 | 14 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 47 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 14 |
| Novolog Flexpen | Insulin Aspart | 42 | 12 |
| Prednisone | Prednisone | 42 | 35 |
| Xarelto | Rivaroxaban | 40 | 13 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | 12 |
| Fenofibrate | Fenofibrate | 36 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 14 |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | suppressed |
| Ozempic | Semaglutide | 34 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 21 |
| Clonazepam | Clonazepam | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Dutasteride | Dutasteride | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | 12 |
| Colchicine | Colchicine | 21 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Simvastatin | Simvastatin | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 16 |
| Cephalexin | Cephalexin | 19 | 17 |
| Pregabalin | Pregabalin | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 18 | 18 |
| Primidone | Primidone | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | 11 |
| Nitroglycerin | Nitroglycerin | 17 | 15 |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Estradiol | Estradiol | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $198.15 · 8 records | Abbott Laboratories | ABRYSVO, COMIRNATY, CONEXTIONS TR TENDON REPAIR SYSTEM-IMPLANT MECHANISM, Cologuard Collection Kit, FREESTYLE LIBRE 3, INSPIRE, PREVNAR 20, SHINGRIX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error